Informing Pharmacokinetic Models With Physiological Data: Oral Population Modeling of L-Serine in Humans
Journal article, 2021

To determine how to set optimal oral L-serine (serine) dose levels for a clinical trial, existing literature was surveyed. Data sufficient to set the dose was inadequate, and so an (n = 10) phase I-A calibration trial was performed, administering serine with and without other oral agents. We analyzed the trial and the literature data using pharmacokinetic (PK) modeling and statistical analysis. The therapeutic goal is to modulate specific serine-related metabolic pathways in the liver using the lowest possible dose which gives the desired effect since the upper bound was expected to be limited by toxicity. A standard PK approach, in which a common model structure was selected using a fit to data, yielded a model with a single central compartment corresponding to plasma, clearance from that compartment, and an endogenous source of serine. To improve conditioning, a parametric structure was changed to estimate ratios (bioavailability over volume, for example). Model fit quality was improved and the uncertainty in estimated parameters was reduced. Because of the particular interest in the fate of serine, the model was used to estimate whether serine is consumed in the gut, absorbed by the liver, or entered the blood in either a free state, or in a protein- or tissue-bound state that is not measured by our assay. The PK model structure was set up to represent relevant physiology, and this quantitative systems biology approach allowed a broader set of physiological data to be used to narrow parameter and prediction confidence intervals, and to better understand the biological meaning of the data. The model results allowed us to determine the optimal human dose for future trials, including a trial design component including IV and tracer studies. A key contribution is that we were able to use human physiological data from the literature to inform the PK model and to set reasonable bounds on parameters, and to improve model conditioning. Leveraging literature data produced a more predictive, useful model.


systems biology

NAFLD (non alcoholic fatty liver disease)

L-Serine (ser)

oral supplementation


Jim Bosley

Clermont Bosley LLC

Elias Björnson

Chalmers, Biology and Biological Engineering, Systems and Synthetic Biology

Sahlgrenska University Hospital

C. Zhang

Royal Institute of Technology (KTH)

Hasan Turkez

Atatürk University

Jens B Nielsen

Chalmers, Biology and Biological Engineering, Systems and Synthetic Biology

Mathias Uhlen

Royal Institute of Technology (KTH)

Jan Borén

Sahlgrenska University Hospital

Adil Mardinoglu

Royal Institute of Technology (KTH)

King's College London

Frontiers in Pharmacology

16639812 (eISSN)

Vol. 12 643179

Subject Categories

Pharmaceutical Sciences

Bioinformatics (Computational Biology)

Probability Theory and Statistics





More information

Latest update

6/9/2021 1